抗核抗体阳性而特异性抗可提取性核抗原抗体阴性的患者对IVF和ICSI胚胎学结局的影响:精子浓度的潜在作用
该研究纳入113例抗核抗体(ANA)阳性且抗可提取性核抗原(ENA)抗体阴性的首次IVF/ICSI助孕女性,与213例匹配的ANA阴性女性比较。结果显示ANA阳性组2PN胚胎、卵裂胚胎、可用胚胎、优质胚胎、囊胚及优质囊胚数均显著减少,精子浓度较高可改善ANA阳性组优质囊胚数。
要点
- ANA阳性且抗ENA抗体阴性的不孕患者首次IVF/ICSI的2PN胚胎、卵裂胚胎、可用胚胎、优质胚胎及囊胚数显著少于ANA阴性者。
- 多变量回归显示ANA阳性是胚胎实验室结局较差的独立危险因素。
- 亚组分析显示较高精子浓度可改善ANA阳性组优质囊胚数,对ANA阴性组无影响。
核心结论
- 血清ANA阳性(无论ENA状态如何)可能对首次IVF/ICSI周期不孕患者的胚胎实验室结局产生不良影响。
- 精子浓度可能改善ANA阳性患者的胚胎结局。
- 对这些患者,抗逆转录病毒治疗(ART)前进行相关ANA检测是必要的。
研究设计与样本
- 纳入113例ANA阳性且抗ENA抗体阴性的首次IVF/ICSI助孕女性,与213例匹配的ANA阴性女性进行比较。
- 比较两组临床特征及IVF/ICSI结局,采用多变量线性回归控制混杂因素评估ANA阳性与实验室结局的关系。
- 亚组分析探索临床因素与ANA状态的交互作用,限制性立方样条(RCS)检验剂量反应关系,事后分析评估结果的准确性和可靠性。
主要发现
- ANA阳性组较ANA阴性组2PN胚胎数显著减少(P=0.022)。
- ANA阳性组较ANA阴性组卵裂胚胎数显著减少(P=0.036),2PN卵裂胚胎数显著减少(P=0.025)。
- ANA阳性组较ANA阴性组可用胚胎数显著减少(P=0.009),优质胚胎数显著减少(P=0.010)。
- ANA阳性组较ANA阴性组囊胚数显著减少(P=0.006),优质囊胚数显著减少(P=0.004)。
- 多变量回归显示ANA阳性是胚胎结局较差的独立危险因素;亚组分析和RCS提示较高精子浓度改善ANA阳性组优质囊胚数,对ANA阴性组无影响。
关键数值与推荐
- ANA阳性组与ANA阴性组相比,2PN胚胎数(P=0.022)、卵裂胚胎数(P=0.036)、2PN卵裂胚胎数(P=0.025)、可用胚胎数(P=0.009)、优质胚胎数(P=0.010)、囊胚数(P=0.006)和优质囊胚数(P=0.004)均显著减少。
- 倾向性评分匹配(PSM)前统计功效超过95.0%,效应量为0.380至0.592;PSM后统计功效降至57.9%至74.2%,效应量为0.252至0.305。
临床怎么用
- 作者认为,血清ANA阳性(无论ENA状态如何)可能对首次IVF/ICSI周期不孕患者的胚胎实验室结局产生不良影响。
- 作者认为,精子浓度可能改善ANA阳性患者的胚胎结局。
- 作者认为,对这些患者,ART前进行相关ANA检测是必要的。
局限性
- 倾向性评分匹配后统计功效降至57.9%至74.2%。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
RESEARCH QUESTION: Anti-extractable nuclear antigens (ENA) and anti-nuclear antibodies (ANA) impair oocyte and embryo quality. What are the embryo laboratory outcomes in ANA-positive but anti-ENA-negative patients? DESIGN: ANA-positive women (n = 113) undergoing their first IVF/ICSI cycle and matched ANA-negative women (n = 213) were included. Clinical characteristics and IVF/ICSI outcomes were compared between groups. Multivariable linear regression controlled for confounders to assess the relationship between ANA positivity and laboratory outcomes. Subgroup analysis explored the interaction between clinical factors and ANA status. Restricted cubic splines (RCS) examined dose-response relationships. Post-hoc analysis assessed the accuracy and reliability of the results. RESULTS: ANA-positive infertile patients had significantly fewer two pronuclei (2PN) embryos (P = 0.022), cleavage embryos (P = 0.036), 2PN cleavage embryos (P = 0.025), available embryos (P = 0.009), high-quality embryos (P = 0.010), blastocysts, (P = 0.006) and high-quality blastocysts (P = 0.004) compared with ANA-negative infertile patients, despite similar clinical characteristics. Multivariable regression identified ANA positivity as an independent risk factor for poorer embryo outcomes. Subgroup analysis and RCS indicated that higher sperm concentration improved high-quality blastocyst numbers in the ANA-positive group, but had no effect in the ANA-negative group. Post-hoc analysis showed statistical power exceeding 95.0% before PSM, with an effect size ranging from 0.380 to 0.592. After PSM, statistical power decreased to 57.9-74.2%, with an effect size of 0.252-0.305. CONCLUSION: ANA positivity in serum, irrespective of ENA status, may adversely affect embryo laboratory outcomes in infertile patients undergoing their first IVF/ICSI cycle. Sperm concentration may improve embryo outcomes in ANA-positive patients. Relevant ANA testing before ART is essential for these patients.
引用
- Ding K, Li X, Jiang W, et al. Effect of anti-nuclear antibody positivity with negative specific anti-extractable anti-nuclear antibodies on IVF and ICSI embryological outcomes: potential role of sperm concentration. Reprod Biomed Online. 2025. PMID: 40992206. doi:10.1016/j.rbmo.2025.105082
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。